John theurer Cancer Center at Hackensack University Medical Center

Hackensack, New Jersey 76520

32 studies enrolling now · 133 studies all time

What they study most

AML, AML With Mutated NPM1, Acute Leukemia, Acute Leukemia (Category), Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, Acute Myeloid Leukemia, Acute Myeloid Leukemia (AML) in Remission, Acute Myeloid Leukemia and Myelodysplastic Syndrome, Adenocarcinoma of Biliary Tract, Advanced Breast Cancer, Advanced Cancer

Studies at this site

• Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII — Recruiting now
• Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer — Recruiting now
• A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis — Recruiting now
• A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) — Recruiting now
• Inobrodib, Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma — Recruiting now
• A Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant Tumors — Recruiting now
• A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma — Recruiting now
• A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206) — Recruiting now
• A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors — Recruiting now
• Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers — Recruiting now
• A Study to Evaluate the Safety, Tolerability, and Efficacy of Escalating Doses of BMS-986463 in Participants With Select Advanced Malignant Tumors. — Recruiting now
• A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma — Recruiting now
• Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome — Recruiting now
• A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies — Recruiting now
• A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma — Recruiting now
• A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors — Recruiting now
• Study of Ifinatamab Deruxtecan (DS-7300a, I-DXd) in Participants With Advanced Solid Malignant Tumors — Recruiting now
• Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia — Recruiting now
• Study of BMS-986497 (ORM-6151) as a Monotherapy, in Double and Triple Combination With Azacitidine and Venetoclax in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome — Recruiting now
• Utility of 18F-rhPSMA-7.3 in the Diagnosis of Prostate Cancer After Focal Gland Treatment — Recruiting now
• Fludarabine and Intermediate-dose TBI Followed by PTCy in Patients Undergoing Allo Transplant for Heme Malignancies — Recruiting now
• Phase IB/II of CPX-351 for Relapse Prevention in AML — Recruiting now
• Neoadjuvant Lu-177-PSMA-617 in Patients With High Risk Localized Prostate Cancer Undergoing Radical Prostatectomy — Recruiting now
• IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301) — Recruiting now
• A Study of BMS-986482 Alone or as Combination Therapy in Participants With Advanced Solid Tumors — Recruiting now
• A Phase II Trial of Sacituzumab Govitecan in Patients With Advanced Thymic Epithelial Tumors — Recruiting now
• RAGE Inhibition to Decrease Cardiotoxicity in Women With Early Breast Cancer — Recruiting now
• Evaluating Novel Therapies in ctDNA Positive GI Cancers — Recruiting now
• A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide — Running, not enrolling
• Study of DSP-0390 in Patients With Recurrent High-Grade Glioma — Running, not enrolling
• Screening for High Frequency Malignant Disease — Running, not enrolling
• Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) — Running, not enrolling
• Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Axicabtagene Ciloleucel — Available (expanded access)
• Study of PF-07265807 in Participants With Metastatic Solid Tumors. — Stopped early
• Study to Test the Safety and Tolerability of PF-07257876 in Participants With Selected Advanced Tumors. — Completed
• Long-term Follow-up Study for Participants of Kite-Sponsored Interventional Studies Treated With Gene-Modified Cells — Enrolling by invitation
• A Study of PF-08046052/SGN-EGFRd2 in Advanced Solid Tumors — Stopped early
• Study to Compare Axicabtagene Ciloleucel With Standard of Care Therapy as First-line Treatment in Participants With High-risk Large B-cell Lymphoma — Running, not enrolling
• Study of Selinexor in Combination With Ruxolitinib in Myelofibrosis — Running, not enrolling
• Study of Lenalidomide in Combination With RICE With Lenalidomide Maintenance Post-Auto Transplant for DLBCL — Completed
• In-vivo Regulatory T Cell Enhancement With Cyclophosphamide and Sirolimus — Stopped early
• Allogeneic Hematopoietic Stem Cell Transplantation for Multiple Myeloma — Completed
• Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Brexucabtagene Autoleucel — Available (expanded access)
• A Study of Venetoclax and Rituximab/Hyaluronidase Human in Relapsed/Refractory CLL — Running, not enrolling
• Vorinostat,Lenalinomide and Dexamethasone in Multiple Myeloma Refractory to Previous Lenalinomide Containing Regimens — Completed
• A Phase II Study of Carfilzomib in Relapsed Waldenström's Macroglobulinemia (WM) IST-CAR-531 — Completed
• Fludarabine and Busulfan vs. Fludarabine, Busulfan and Total Body Irradiation — Stopped early
• Escalating Doses of Thalidomide in Conjunction With Bortezomib and HIgh Dose Melphalan for BSCT — Completed
• Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors — Running, not enrolling
• An Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With High-Risk Multiple Myeloma — Completed